lenalidomide (Revlimid)

  • Medical Editor: Jay W. Marks, MD
    Jay W. Marks, MD

    Jay W. Marks, MD

    Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.

  • Pharmacy Author: Omudhome Ogbru, PharmD
    Omudhome Ogbru, PharmD

    Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

Cancer 101: Cancer Explained

What is lenalidomide Revlimid, and how does it work (mechanism of action)?

Lenalidomide (Revlimid) is an oral anti-cancer medication. Lenalidomide is similar to thalidomide (Thalomid), an older cancer medicine that, although effective, was associated with serious side effects. The exact mechanism through which lenalidomide stops the growth of cancer cells is not understood. Lenalidomide stimulates or regulates the body's immune system to attack and kill cancer cells, reduces the formation of new blood vessels that supply nutrients to the cancer cells, and prevents or stops growth of the cancer. Laboratory studies have shown that lenalidomide inhibits cancer growth and causes programmed cell death in certain types of cancers, including multiple myeloma, mantle cell lymphoma, and del (5q) myelodysplastic syndromes. Lenalidomide was approved by the FDA Dec. 27, 2005.

What brand names are available for lenalidomide Revlimid?


Is lenalidomide Revlimid available as a generic drug?


Do I need a prescription for lenalidomide Revlimid?


What are the side effects of lenalidomide Revlimid?

Common side effects of lenalidomide are:

Lenalidomide may cause some other rare but serious side effects. These include:

  • increase risk of death in patients who have chronic lymphocytic leukemia (CLL);
  • risk of new cancers;
  • severe liver problems;
  • serious skin reactions;
  • tumor lysis syndrome, or TLS (caused by the fast breakdown of cancer cells);
  • formation of blood clots in the arteries, veins, and lungs;
  • serious birth defects or death of an unborn baby;
  • and worsening of tumors.

Quick GuidePancreatic Cancer Symptoms, Causes, and Treatment

Pancreatic Cancer Symptoms, Causes, and Treatment

What is the dosage for lenalidomide Revlimid?

Lenalidomide capsules should be swallowed whole with water around the same time each day.

Multiple myeloma (MM): the recommended starting dose of lenalidomide is 25 mg by mouth once a day on day 1-21 of repeated 28-day cycles. The recommended dose of dexamethasone is 40 mg once daily on day 1-4, 9-12, and 17-20 of each 28-day cycle for the first 4 cycles of therapy, followed by 40 mg once daily on day 1-4 every 28 days thereafter.

Myelodysplastic syndrome (MDS): the recommended starting dose of lenalidomide is 10 mg by mouth once a day.

Mantle cell lymphoma (MCL): the recommended starting dose of lenalidomide is 25 mg by mouth once a day on days 1-21 of repeated 28 cycles.

As lenalidomide is primarily cleared from the body via the kidneys, dose adjustments are recommended in patients with moderate or severe kidney disease and in patients on dialysis.

Which drugs or supplements interact with lenalidomide Revlimid?

When multiple doses of lenalidomide were administered with digoxin, the blood levels of digoxin were increased. Patients receiving both medications should be closely monitored to minimize the occurrence of unwanted side effects.

Due to the increased risk of forming blood clots in the arteries, veins, or lungs, lenalidomide should be used cautiously in patients using erythropoietin-stimulating agents and estrogen-containing therapies.

Is lenalidomide Revlimid safe to take if I'm pregnant or breastfeeding?

Lenalidomide is similar to thalidomide which is a known human teratogen that causes life-threatening human birth defects or embryo-fetal death. It should not be used during pregnancy. Lenalidomide is classified as FDA pregnancy risk category X (animal and human studies have demonstrated harm to the fetus). A program called Revlimid REMS was developed to prevent fetal exposure to lenalidomide. Patients, prescribers, and pharmacies must be registered in the Revlimid REMS programs to receive, prescribe, and dispense lenalidomide.

Females must not get pregnant for 4 weeks before starting lenalidomide, while taking lenalidomide, during any breaks in treatment, and for 4 weeks after stopping lenalidomide.

As lenalidomide may pass into human semen, all males taking lenalidomide must use a latex or synthetic condom during any sexual contact with a pregnant female or a female who can become pregnant. Male patients should not donate sperm while taking lenalidomide, during any breaks in treatment, and for 4 weeks after stopping lenalidomide.

Lenalidomide should not be used by females who are breastfeeding. It is not known whether lenalidomide is excreted in breast milk and its effect on the nursing infant.

What else should I know about lenalidomide Revlimid?

What preparations of lenalidomide Revlimid are available?

Oral capsules: 2.5, 5, 10, 15, 20, and 25 mg.

How should I keep lenalidomide Revlimid stored?

Capsules should be stored at room temperature, between 15 C and 30 C (59 F to 86 F). It is extremely important to keep this medication away from children, pets, and pregnant females due to the high risk of serious side effects associated with accidental exposure.

REFERENCE: FDA Prescribing Information

Last Editorial Review: 3/25/2015

Subscribe to MedicineNet's Cancer Report Newsletter

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Reviewed on 3/25/2015
REFERENCE: FDA Prescribing Information

Health Solutions From Our Sponsors